Research Area: Brain Imaging

brain mapping, functional connectivity, fMRI, EEG, MEG, predictive imaging, precision interventions, contrast agents, theory of mind, the developing brain, learning

Alan Jasanoff

Next Generation Brain Imaging

One of the greatest challenges of modern neuroscience is to relate high-level operations of the brain and mind to well-defined biological processes that arise from molecules and cells. The Jasanoff lab is creating a suite of experimental approaches designed to achieve this by permitting brain-wide dynamics of neural signaling and plasticity to be imaged for the first time, with molecular specificity. These potentially transformative approaches use novel probes detectable by magnetic resonance imaging (MRI) and other noninvasive readouts. The probes afford qualitatively new ways to study healthy and pathological aspects of integrated brain function in mechanistically-informative detail, in animals and possibly also people.

Dimitrios Pantazis

Holistic Imagery

The most widely used imaging method, functional magnetic resonance imaging (fMRI) provides precise information about where in the brain activity occurs, but it cannot detect with the same degree of precision when these events occur in the brain. This kind of temporal precision can be accomplished with magnetoencephalography (MEG), a tool developed at MIT and found in the Martinos Imaging Center at MIT.  Dimitrios Pantazis’ research helps to bridge the gap between spatial and temporal brain imaging data. Director of the MEG lab, Pantazis develops new methods for extracting neural representations from MEG data, and the development of multimodal imaging techniques that give more holistic information about brain function. Using such approaches, he gets insight into processes such as how the brain handles information in the ventral visual stream.

Nancy Kanwisher

Architecture of the Mind

What is the nature of the human mind? Philosophers have debated this question for centuries, but Nancy Kanwisher approaches this question empirically, using brain imaging to look for components of the human mind that reside in particular regions of the brain. Her lab has identified cortical regions that are selectively engaged in the perception of faces, places, and bodies, and other regions specialized for uniquely human functions including the music, language, and thinking about other people’s thoughts. More recently, her lab has begun using artificial neural networks to unpack these findings and examine why, from a computational standpoint, the brain exhibits functional specification in the first place.

John Gabrieli

Images of Mind

John Gabrieli’s goal is to understand the organization of memory, thought, and emotion in the human brain. In collaboration with clinical colleagues, Gabrieli uses brain imaging to better understand, diagnose, and select treatments for neurological and psychiatric diseases.

A major focus of the Gabrieli lab is the neural basis of learning in children. His team found structural differences in the brains of young children who are at risk for reading difficulties, even before they start learning to read. By studying these differences in children, Gabrieli hopes to identify ways to improve learning in the classroom and inform effective educational policies and practices.

Gabrieli is also interested in using the tools of neuroscience to personalize medicine. His team showed that brain scans can identify children who are vulnerable to depression before symptoms even appear, opening the possibility of earlier interventions to prevent episodes of depression. Brain scans may also help help predict which individuals with social anxiety disorder are most likely to benefit from a particular therapeutic intervention. Gabrieli’s team continues to explore the role of neuroimaging in other brain disorders, including schizophrenia, addiction, and bipolar disorder.

His team also studies a range of other research topics, including new strategies to cope with emotional stress, the benefits of mindfulness for academic performance and mental health, and the value of embracing neurodiversity to better understand autism.

Satrajit Ghosh

Personalized Medicine

A fundamental problem in psychiatry is that there are no biological markers for diagnosing mental illness or for indicating how best to treat it. Treatment decisions are based entirely on symptoms, and doctors and their patients will typically try one treatment, then if it does not work, try another, and perhaps another. Satrajit Ghosh hopes to change this picture, and his research suggests that individual brain scans and speaking patterns can hold valuable information for guiding psychiatrists and patients. His research group develops novel analytic platforms that use such information to create robust, predictive models around human health. Current areas include depression, suicide, anxiety disorders, autism, Parkinson’s disease, and brain tumors.

Robert Desimone

Paying Attention

Our brains are constantly bombarded with sensory information. The ability to distinguish relevant information from irrelevant distractions is a critical skill, one that is impaired in many brain disorders. By studying the visual system of humans and animals, Robert Desimone has shown that when we attend to something specific, neurons in certain brain regions fire in unison – like a chorus rising above the noise – allowing the relevant information to be “heard” more efficiently by other regions of the brain.

Brain activity pattern may be early sign of schizophrenia

Anne Trafton |

Schizophrenia, a brain disorder that produces hallucinations, delusions, and cognitive impairments, usually strikes during adolescence or young adulthood. While some signs can suggest that a person is at high risk for developing the disorder, there is no way to definitively diagnose it until the first psychotic episode occurs.

MIT neuroscientists working with researchers at Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, and the Shanghai Mental Health Center have now identified a pattern of brain activity correlated with development of schizophrenia, which they say could be used as a marker to diagnose the disease earlier.

“You can consider this pattern to be a risk factor. If we use these types of brain measurements, then maybe we can predict a little bit better who will end up developing psychosis, and that may also help tailor interventions,” says Guusje Collin, a visiting scientist at MIT’s McGovern Institute for Brain Research and the lead author of the paper.

The study, which appeared in the journal Molecular Psychiatry on Nov. 8, was performed at the Shanghai Mental Health Center. Susan Whitfield-Gabrieli, a visiting scientist at the McGovern Institute and a professor of psychology at Northeastern University, is one of the principal investigators for the study, along with Jijun Wang of the Shanghai Mental Health Center, William Stone of Beth Israel Deaconess Medical Center, the late Larry Seidman of Beth Israel Deaconess Medical Center, and Martha Shenton of Brigham and Women’s Hospital.

Abnormal connections

Before they experience a psychotic episode, characterized by sudden changes in behavior and a loss of touch with reality, patients can experience milder symptoms such as disordered thinking. This kind of thinking can lead to behaviors such as jumping from topic to topic at random, or giving answers unrelated to the original question. Previous studies have shown that about 25 percent of people who experience these early symptoms go on to develop schizophrenia.

The research team performed the study at the Shanghai Mental Health Center because the huge volume of patients who visit the hospital annually gave them a large enough sample of people at high risk of developing schizophrenia.

The researchers followed 158 people between the ages of 13 and 34 who were identified as high-risk because they had experienced early symptoms. The team also included 93 control subjects, who did not have any risk factors. At the beginning of the study, the researchers used functional magnetic resonance imaging (fMRI) to measure a type of brain activity involving “resting state networks.” Resting state networks consist of brain regions that preferentially connect with and communicate with each other when the brain is not performing any particular cognitive task.

“We were interested in looking at the intrinsic functional architecture of the brain to see if we could detect early aberrant brain connectivity or networks in individuals who are in the clinically high-risk phase of the disorder,” Whitfield-Gabrieli says.

One year after the initial scans, 23 of the high-risk patients had experienced a psychotic episode and were diagnosed with schizophrenia. In those patients’ scans, taken before their diagnosis, the researchers found a distinctive pattern of activity that was different from the healthy control subjects and the at-risk subjects who had not developed psychosis.

For example, in most people, a part of the brain known as the superior temporal gyrus, which is involved in auditory processing, is highly connected to brain regions involved in sensory perception and motor control. However, in patients who developed psychosis, the superior temporal gyrus became more connected to limbic regions, which are involved in processing emotions. This could help explain why patients with schizophrenia usually experience auditory hallucinations, the researchers say.

Meanwhile, the high-risk subjects who did not develop psychosis showed network connectivity nearly identical to that of the healthy subjects.

Early intervention

This type of distinctive brain activity could be useful as an early indicator of schizophrenia, especially since it is possible that it could be seen in even younger patients. The researchers are now performing similar studies with younger at-risk populations, including children with a family history of schizophrenia.

“That really gets at the heart of how we can translate this clinically, because we can get in earlier and earlier to identify aberrant networks in the hopes that we can do earlier interventions, and possibly even prevent psychiatric disorders,” Whitfield-Gabrieli says.

She and her colleagues are now testing early interventions that could help to combat the symptoms of schizophrenia, including cognitive behavioral therapy and neural feedback. The neural feedback approach involves training patients to use mindfulness meditation to reduce activity in the superior temporal gyrus, which tends to increase before and during auditory hallucinations.

The researchers also plan to continue following the patients in the current study, and they are now analyzing some additional data on the white matter connections in the brains of these patients, to see if those connections might yield additional differences that could also serve as early indicators of disease.

The research was funded by the National Institutes of Health, the Ministry of Science and Technology of China, and the Poitras Center for Psychiatric Disorders Research at MIT. Collin was supported by a Marie Curie Global Fellowship grant from the European Commission.

Is it worth the risk?

by Shannon Fischer |

During the Klondike Gold Rush, thousands of prospectors climbed Alaska’s dangerous Chilkoot Pass in search of riches. McGovern scientists are exploring how a once-overlooked part of the brain might be at the root of cost-benefit decisions like these. McGovern researchers are studying how the brain balances risk and reward to make decisions.

Is it worth speeding up on the highway to save a few minutes’ time? How about accepting a job that pays more, but requires longer hours in the office?

Scientists call these types of real-life situations cost-benefit conflicts. Choosing well is an essential survival ability—consider the animal that must decide when to expose itself to predation to gather more food.

Now, McGovern researchers are discovering that this fundamental capacity to make decisions may originate in the basal ganglia—a brain region once considered unimportant to the human
experience—and that circuits associated with this structure may play a critical role in determining our state of mind.

Anatomy of decision-making

A few years back, McGovern investigator Ann Graybiel noticed that in the brain imaging literature, a specific part of the cortex called the pregenual anterior cingulate cortex or pACC, was implicated in certain psychiatric disorders as well as tasks involving cost-benefit decisions. Thanks to her now classic neuroanatomical work defining the complex anatomy and function of the basal ganglia, Graybiel knew that the pACC projected back into the basal ganglia—including its largest cluster of neurons, the striatum.

The striatum sits beneath the cortex, with a mouse-like main body and curving tail. It seems to serve as a critical way-station, communicating with both the brain’s sensory and motor areas above, and the limbic system (linked to emotion and memory) below. Running through the striatum are striosomes, column-like neurochemical compartments. They wire down to a small, but important part of the brain called the substantia nigra, which houses the huge majority of the brain’s dopamine neurons—a key neurochemical heavily involved, much like the basal ganglia as a whole, in reward, learning, and movement. The pACC region related to mood control targeted these striosomes, setting up a communication line from the neocortex to the dopamine neurons.

Graybiel discovered these striosomes early in her career, and understood them to have distinct wiring from other compartments in the striatum, but picking out these small, hard-to-find striosomes posed a technological challenge—so it was exciting to have this intriguing link to the pACC and mood disorders.

Working with Ken-ichi Amemori, then a research scientist in her lab, she adapted a common human cost-benefit conflict test for macaque monkeys. The monkeys could elect to receive a food treat, but the treat would always be accompanied by an annoying puff of air to the eyes. Before they decided, a visual cue told them exactly how much treat they could get, and exactly how strong the air puff would be, so they could choose if the treat was worth it.

Normal monkeys varied their choices in a fairly rational manner, rejecting the treat whenever it seemed like the air puff was too strong, or the treat too small to be worth it—and this corresponded with activity in the pACC neurons. Interestingly, they found that some pACC neurons respond more when animals approach the combined offers, while other pACC neurons
fire more when the animals avoid the offers. “It is as though there are two opposing armies. And the one that wins, controls the state of the animal.” Moreover, when Graybiel’s team electrically stimulated these pACC neurons, the animals begin to avoid the offers, even offers that they normally would approach. “It is as though when the stimulation is on, they think the future is worse than it really is,” Graybiel says.

Intriguingly, this effect only worked in situations where the animal had to weigh the value of a cost against a benefit. It had no effect on a decision between two negatives or two positives, like two different sizes of treats. The anxiety drug diazepam also reversed the stimulatory effect, but again, only on cost-benefit choices. “This particular kind of mood-influenced cost-benefit
decision-making occurs not only under conflict conditions but in our regular day to day lives. For example: I know that if I eat too much chocolate, I might get fat, but I love it, I want it.”

Glass half empty

Over the next few years, Graybiel, with another research scientist in her lab, Alexander Friedman, unraveled the circuit behind the macaques’ choices. They adapted the test for rats and mice,
so that they could more easily combine the cellular and molecular technologies needed to study striosomes, such as optogenetics and mouse engineering.

They found that the cortex (specifically, the pre-limbic region of the prefrontal cortex in rodents) wires onto both striosomes and fast-acting interneurons that also target the striosomes. In a
healthy circuit, these interneurons keep the striosomes in check by firing off fast inhibitory signals, hitting the brakes before the striosome can get started. But if the researchers broke that corticalstriatal connection with optogenetics or chronic stress, the animals became reckless, going for the high-risk, high-reward arm of the maze like a gambler throwing caution to the wind. If they amplified this inhibitory interneuron activity, they saw the opposite effect. With these techniques, they could block the effects of prior chronic stress.

This summer, Graybiel and Amemori published another paper furthering the story and returning to macaques. It was still too difficult to hit striosomes, and the researchers could only stimulate the striatum more generally. However, they replicated the effects in past studies.

Many electrodes had no effect, a small number made the monkeys choose the reward more often. Nearly a quarter though made the monkeys more avoidant—and this effect correlated with a change in the macaques’ brainwaves in a manner reminiscent of patients with depression.

But the surprise came when the avoidant-producing stimulation was turned off, the effects lasted unexpectedly long, only returning to normal on the third day.

Graybiel was stunned. “This is very important, because changes in the brain can get set off and have a life of their own,” she says. “This is true for some individuals who have had a terrible experience, and then live with the aftermath, even to the point of suffering from post-traumatic stress disorder.”

She suspects that this persistent state may actually be a form of affect, or mood. “When we change this decision boundary, we’re changing the mood, such that the animal overestimates cost, relative to benefit,” she explains. “This might be like a proxy state for pessimistic decision-making experienced during anxiety and depression, but may also occur, in a milder form, in you and me.”

Graybiel theorizes that this may tie back into the dopamine neurons that the striosomes project to: if this avoidance behavior is akin to avoidance observed in rodents, then they are stimulating a circuit that ultimately projects to dopamine neurons of the substantia nigra. There, she believes, they could act to suppress these dopamine neurons, which in turn project to the rest of the brain, creating some sort of long-term change in their neural activity. Or, put more simply, stimulation of these circuits creates a depressive funk.

Bottom up

Three floors below the Graybiel lab, postdoc Will Menegas is in the early stages of his own work untangling the role of dopamine and the striatum in decision-making. He joined Guoping Feng’s lab this summer after exploring the understudied “tail of the striatum” at Harvard University.

While dopamine pathways influence many parts of the brain, examination of connections to the striatum have largely focused on the frontmost part of the striatum, associated with valuations.

But as Menegas showed while at Harvard, dopamine neurons that project to the rear of the striatum are different. Those neurons get their input from parts of the brain associated with general arousal and sensation—and instead of responding to rewards, they respond to novelty and intense stimuli, like air puffs and loud noises.

In a new study published in Nature Neuroscience, Menegas used a neurotoxin to disrupt the dopamine projection from the substantia nigra to the posterior striatum to see how this circuit influences behavior. Normal mice approach novel items cautiously and back away after sniffing at them, but the mice in Menegas’ study failed to back away. They stopped avoiding a port that gave an air puff to the face and they didn’t behave like normal mice when Menegas dropped a strange or new object—say, a lego—into their cage. Disrupting the nigral-posterior striatum
seemed to turn off their avoidance habit.

“These neurons reinforce avoidance the same way that canonical dopamine neurons reinforce approach,” Menegas explains. It’s a new role for dopamine, suggesting that there may be two different and distinct systems of reinforcement, led by the same neuromodulator in different parts of the striatum.

This research, and Graybiel’s discoveries on cost-benefit decision circuits, share clear parallels, though the precise links between the two phenomena are yet to be fully determined. Menegas plans to extend this line of research into social behavior and related disorders like autism in marmoset monkeys.

“Will wants to learn the methods that we use in our lab to work on marmosets,” Graybiel says. “I think that working together, this could become a wonderful story, because it would involve social interactions.”

“This a very new angle, and it could really change our views of how the reward system works,” Feng says. “And we have very little understanding of social circuits so far and especially in higher organisms, so I think this would be very exciting. Whatever we learn, it’s going to be new.”

Human choices

Based on their preexisting work, Graybiel’s and Menegas’ projects are well-developed—but they are far from the only McGovern-based explorations into ways this brain region taps into our behaviors. Maiya Geddes, a visiting scientist in John Gabrieli’s lab, has recently published a paper exploring the little-known ways that aging affects the dopamine-based nigral-striatum-hippocampus learning and memory systems.

In Rebecca Saxe’s lab, postdoc Livia Tomova just kicked off a new pilot project using brain imaging to uncover dopamine-striatal circuitry behind social craving in humans and the urge to rejoin peers. “Could there be a craving response similar to hunger?” Tomova wonders. “No one has looked yet at the neural mechanisms of this.”

Graybiel also hopes to translate her findings into humans, beginning with collaborations at the Pizzagalli lab at McLean Hospital in Belmont. They are using fMRI to study whether patients
with anxiety and depression show some of the same dysfunctions in the cortico-striatal circuitry that she discovered in her macaques.

If she’s right about tapping into mood states and affect, it would be an expanded role for the striatum—and one with significant potential therapeutic benefits. “Affect state” colors many psychological functions and disorders, from memory and perception, to depression, chronic stress, obsessive-compulsive disorder, and PTSD.

For a region of the brain once dismissed as inconsequential, McGovern researchers have shown the basal ganglia to influence not only our choices but our state of mind—suggesting that this “primitive” brain region may actually be at the heart of the human experience.

 

 

Monitoring electromagnetic signals in the brain with MRI

Anne Trafton |

Researchers commonly study brain function by monitoring two types of electromagnetism — electric fields and light. However, most methods for measuring these phenomena in the brain are very invasive.

MIT engineers have now devised a new technique to detect either electrical activity or optical signals in the brain using a minimally invasive sensor for magnetic resonance imaging (MRI).

MRI is often used to measure changes in blood flow that indirectly represent brain activity, but the MIT team has devised a new type of MRI sensor that can detect tiny electrical currents, as well as light produced by luminescent proteins. (Electrical impulses arise from the brain’s internal communications, and optical signals can be produced by a variety of molecules developed by chemists and bioengineers.)

“MRI offers a way to sense things from the outside of the body in a minimally invasive fashion,” says Aviad Hai, an MIT postdoc and the lead author of the study. “It does not require a wired connection into the brain. We can implant the sensor and just leave it there.”

This kind of sensor could give neuroscientists a spatially accurate way to pinpoint electrical activity in the brain. It can also be used to measure light, and could be adapted to measure chemicals such as glucose, the researchers say.

Alan Jasanoff, an MIT professor of biological engineering, brain and cognitive sciences, and nuclear science and engineering, and an associate member of MIT’s McGovern Institute for Brain Research, is the senior author of the paper, which appears in the Oct. 22 issue of Nature Biomedical Engineering. Postdocs Virginia Spanoudaki and Benjamin Bartelle are also authors of the paper.

Detecting electric fields

Jasanoff’s lab has previously developed MRI sensors that can detect calcium and neurotransmitters such as serotonin and dopamine. In this paper, they wanted to expand their approach to detecting biophysical phenomena such as electricity and light. Currently, the most accurate way to monitor electrical activity in the brain is by inserting an electrode, which is very invasive and can cause tissue damage. Electroencephalography (EEG) is a noninvasive way to measure electrical activity in the brain, but this method cannot pinpoint the origin of the activity.

To create a sensor that could detect electromagnetic fields with spatial precision, the researchers realized they could use an electronic device — specifically, a tiny radio antenna.

MRI works by detecting radio waves emitted by the nuclei of hydrogen atoms in water. These signals are usually detected by a large radio antenna within an MRI scanner. For this study, the MIT team shrank the radio antenna down to just a few millimeters in size so that it could be implanted directly into the brain to receive the radio waves generated by water in the brain tissue.

The sensor is initially tuned to the same frequency as the radio waves emitted by the hydrogen atoms. When the sensor picks up an electromagnetic signal from the tissue, its tuning changes and the sensor no longer matches the frequency of the hydrogen atoms. When this happens, a weaker image arises when the sensor is scanned by an external MRI machine.

The researchers demonstrated that the sensors can pick up electrical signals similar to those produced by action potentials (the electrical impulses fired by single neurons), or local field potentials (the sum of electrical currents produced by a group of neurons).

“We showed that these devices are sensitive to biological-scale potentials, on the order of millivolts, which are comparable to what biological tissue generates, especially in the brain,” Jasanoff says.

The researchers performed additional tests in rats to study whether the sensors could pick up signals in living brain tissue. For those experiments, they designed the sensors to detect light emitted by cells engineered to express the protein luciferase.

Normally, luciferase’s exact location cannot be determined when it is deep within the brain or other tissues, so the new sensor offers a way to expand the usefulness of luciferase and more precisely pinpoint the cells that are emitting light, the researchers say. Luciferase is commonly engineered into cells along with another gene of interest, allowing researchers to determine whether the genes have been successfully incorporated by measuring the light produced.

Smaller sensors

One major advantage of this sensor is that it does not need to carry any kind of power supply, because the radio signals that the external MRI scanner emits are enough to power the sensor.

Hai, who will be joining the faculty at the University of Wisconsin at Madison in January, plans to further miniaturize the sensors so that more of them can be injected, enabling the imaging of light or electrical fields over a larger brain area. In this paper, the researchers performed modeling that showed that a 250-micron sensor (a few tenths of a millimeter) should be able to detect electrical activity on the order of 100 millivolts, similar to the amount of current in a neural action potential.

Jasanoff’s lab is interested in using this type of sensor to detect neural signals in the brain, and they envision that it could also be used to monitor electromagnetic phenomena elsewhere in the body, including muscle contractions or cardiac activity.

“If the sensors were on the order of hundreds of microns, which is what the modeling suggests is in the future for this technology, then you could imagine taking a syringe and distributing a whole bunch of them and just leaving them there,” Jasanoff says. “What this would do is provide many local readouts by having sensors distributed all over the tissue.”

The research was funded by the National Institutes of Health.

New sensors track dopamine in the brain for more than a year

Anne Trafton |

Dopamine, a signaling molecule used throughout the brain, plays a major role in regulating our mood, as well as controlling movement. Many disorders, including Parkinson’s disease, depression, and schizophrenia, are linked to dopamine deficiencies.

MIT neuroscientists have now devised a way to measure dopamine in the brain for more than a year, which they believe will help them to learn much more about its role in both healthy and diseased brains.

“Despite all that is known about dopamine as a crucial signaling molecule in the brain, implicated in neurologic and neuropsychiatric conditions as well as our ability to learn, it has been impossible to monitor changes in the online release of dopamine over time periods long enough to relate these to clinical conditions,” says Ann Graybiel, an MIT Institute Professor, a member of MIT’s McGovern Institute for Brain Research, and one of the senior authors of the study.

Michael Cima, the David H. Koch Professor of Engineering in the Department of Materials Science and Engineering and a member of MIT’s Koch Institute for Integrative Cancer Research, and Rober Langer, the David H. Koch Institute Professor and a member of the Koch Institute, are also senior authors of the study. MIT postdoc Helen Schwerdt is the lead author of the paper, which appears in the Sept. 12 issue of Communications Biology.

Long-term sensing

Dopamine is one of many neurotransmitters that neurons in the brain use to communicate with each other. Traditional systems for measuring dopamine — carbon electrodes with a shaft diameter of about 100 microns — can only be used reliably for about a day because they produce scar tissue that interferes with the electrodes’ ability to interact with dopamine.

In 2015, the MIT team demonstrated that tiny microfabricated sensors could be used to measure dopamine levels in a part of the brain called the striatum, which contains dopamine-producing cells that are critical for habit formation and reward-reinforced learning.

Because these probes are so small (about 10 microns in diameter), the researchers could implant up to 16 of them to measure dopamine levels in different parts of the striatum. In the new study, the researchers wanted to test whether they could use these sensors for long-term dopamine tracking.

“Our fundamental goal from the very beginning was to make the sensors work over a long period of time and produce accurate readings from day to day,” Schwerdt says. “This is necessary if you want to understand how these signals mediate specific diseases or conditions.”

To develop a sensor that can be accurate over long periods of time, the researchers had to make sure that it would not provoke an immune reaction, to avoid the scar tissue that interferes with the accuracy of the readings.

The MIT team found that their tiny sensors were nearly invisible to the immune system, even over extended periods of time. After the sensors were implanted, populations of microglia (immune cells that respond to short-term damage), and astrocytes, which respond over longer periods, were the same as those in brain tissue that did not have the probes inserted.

In this study, the researchers implanted three to five sensors per animal, about 5 millimeters deep, in the striatum. They took readings every few weeks, after stimulating dopamine release from the brainstem, which travels to the striatum. They found that the measurements remained consistent for up to 393 days.

“This is the first time that anyone’s shown that these sensors work for more than a few months. That gives us a lot of confidence that these kinds of sensors might be feasible for human use someday,” Schwerdt says.

Paul Glimcher, a professor of physiology and neuroscience at New York University, says the new sensors should enable more researchers to perform long-term studies of dopamine, which is essential for studying phenomena such as learning, which occurs over long time periods.

“This is a really solid engineering accomplishment that moves the field forward,” says Glimcher, who was not involved in the research. “This dramatically improves the technology in a way that makes it accessible to a lot of labs.”

Monitoring Parkinson’s

If developed for use in humans, these sensors could be useful for monitoring Parkinson’s patients who receive deep brain stimulation, the researchers say. This treatment involves implanting an electrode that delivers electrical impulses to a structure deep within the brain. Using a sensor to monitor dopamine levels could help doctors deliver the stimulation more selectively, only when it is needed.

The researchers are now looking into adapting the sensors to measure other neurotransmitters in the brain, and to measure electrical signals, which can also be disrupted in Parkinson’s and other diseases.

“Understanding those relationships between chemical and electrical activity will be really important to understanding all of the issues that you see in Parkinson’s,” Schwerdt says.

The research was funded by the National Institute of Biomedical Imaging and Bioengineering, the National Institute of Neurological Disorders and Stroke, the Army Research Office, the Saks Kavanaugh Foundation, the Nancy Lurie Marks Family Foundation, and Dr. Tenley Albright.